↓ Skip to main content

Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression

Overview of attention for article published in Frontiers in Psychiatry, September 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
6 X users

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression
Published in
Frontiers in Psychiatry, September 2018
DOI 10.3389/fpsyt.2018.00424
Pubmed ID
Authors

Johannes A. C. Laferton, Sagar Vijapura, Lee Baer, Alisabet J. Clain, Abigail Cooper, George Papakostas, Lawrence H. Price, Linda L. Carpenter, Audrey R. Tyrka, Maurizio Fava, David Mischoulon

Abstract

Objective: It has been suggested that patients' perception of treatment assignment might serve to bias results of double blind randomized controlled trials (RCT). Most previous evidence on the effects of patients' perceptions and the mechanisms influencing these perceptions relies on cross-sectional associations. This re-analysis of a double blind, placebo controlled RCT of pharmacological treatment of major depression set out to gather longitudinal evidence on the mechanism and effects of patients' perceived treatment assignment in the pharmacological treatment of major depression. Methods: One-hundred eighty-nine outpatients with DSM-IV diagnosed major depression were randomized to SAMe 1,600-3,200 mg/d, escitalopram 10-20 mg/days, or placebo for 12 weeks. Data on depressive symptoms (17-item Hamilton Depression Scale; HDRS-17), adverse events and patients' perceived treatment assignment was collected at baseline, week 6, and week 12. The re-analysis focused on N = 166 (out of the originally included 189 participants) with available data on perceived treatment assignment. Results: As in the parent trial, depressive symptoms (HDRS-17) significantly decreased over the course of 12 weeks and there was no difference between placebo, SAMe or escitalopram. A significant number of patients changed their perceptions about treatment assignment throughout the trial, especially between baseline and week 6. Improvement in depressive symptoms, but not adverse events significantly predicted perceived treatment assignment at week 6. In turn, perceived treatment assignment at week 6, but not actual treatment, predicted further improvement in depressive symptoms at week 12. Conclusions: The current results provide longitudinal evidence that patients' perception of treatment assignment systematically change despite a double blind procedure and in turn might trigger expectancy effects with the potential to bias the validity of an RCT. Parent study grant number: R01 AT001638 Parent study ClinicalTrials. gov Identifier: NCT00101452.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 16%
Student > Ph. D. Student 6 14%
Researcher 5 11%
Other 3 7%
Student > Master 3 7%
Other 4 9%
Unknown 16 36%
Readers by discipline Count As %
Medicine and Dentistry 11 25%
Psychology 9 20%
Neuroscience 2 5%
Social Sciences 2 5%
Nursing and Health Professions 1 2%
Other 1 2%
Unknown 18 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 October 2022.
All research outputs
#7,101,359
of 23,504,694 outputs
Outputs from Frontiers in Psychiatry
#3,148
of 10,610 outputs
Outputs of similar age
#121,945
of 337,112 outputs
Outputs of similar age from Frontiers in Psychiatry
#94
of 189 outputs
Altmetric has tracked 23,504,694 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 10,610 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 337,112 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 189 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.